Hostname: page-component-8448b6f56d-qsmjn Total loading time: 0 Render date: 2024-04-25T02:33:39.678Z Has data issue: false hasContentIssue false

The IOM D-lemma

Published online by Cambridge University Press:  15 April 2011

Michael F. Holick*
Affiliation:
Boston University Medical Center, 85 East Newton Street, M-1013, Boston, MA 02118, USA
*
Rights & Permissions [Opens in a new window]

Abstract

Type
Letters to the Editor
Copyright
Copyright © The Author 2011

Madam

It was with great anticipation that the world waited for the release of the recommendations on vitamin D by the Institute of Medicine (IOM), which finally made its debut in November 2010(1). The committee relied on several large meta-analyses including those from the Agency for Healthcare Research and Quality from the USA and Canada as well as larger randomized controlled trials (RCT), and concluded that the previous recommendations made by the IOM in 1997 were woefully inadequate. The committee recognized that, at a minimum, most children and adults should increase their vitamin D intake by 200%, i.e. from 5 to 15 μg vitamin D/d to maintain a healthy skeleton. For adults over the age of 70 years the committee recommended 20 μg vitamin D/d. The committee also appreciated that vitamin D is not as toxic as once thought and therefore doubled the tolerable upper limit from 50 to 100 μg/d for most children and all adults.

There are several thousand publications suggesting that vitamin D deficiency and insufficiency defined as 25-hydroxyvitamin D level <30 ng/ml is a pandemic affecting all populations with serious health consequences(Reference Wang, Pencina and Booth2Reference Moan, Porojnicu and Dahlback10). However the IOM concluded based on its definition of vitamin D deficiency, i.e. 25-hydroxyvitamin D <20 ng/ml, that this is a relatively rare deficiency in the USA. The IOM only recognized that vitamin D was beneficial for musculoskeletal health and dismissed a multitude of association studies and small RCT suggesting other health benefits, including improving immune and neurocognitive functions(1, Reference Brehm, Schuemann and Fuhlbrigge11, Reference Urashima, Segawa and Okazaki12) and reducing the risk of deadly cancers(Reference Grant13, Reference Lappe, Travers-Gustafson and Davies14), heart disease(Reference Wang, Pencina and Booth2Reference Dong, Stallmann-Jorgenson and Pollock6), autoimmune diseases(Reference Holick15) and type 2 diabetes(Reference Holick15). The IOM did recognize that many tissues and cells in the body express a vitamin D receptor and that some cells including macrophages have the capability of activating vitamin D locally(Reference Adams and Hewison16). However they did not consider the health implications for why so many cells in the body would have a vitamin D receptor and therefore presumably require 1,25-dihydroxyvitamin D for maximum function and health.

The IOM also suggested based on a few studies that there may be a higher mortality associated with blood levels of 25-hydroxyvitamin D between <20 and >30 ng/ml. However, at least one of the studies it included in the analysis noted there was a lower risk of mortality for 25-hydroxyvitamin D concentrations between 30 and 49 ng/ml and a concentration >50 ng/ml was associated with a higher risk of mortality in women but not in men(Reference Melamed, Michos and Post4).

There have now been several RCT demonstrating that ingesting between 25 and 50μg vitamin D/d and/or attaining a blood level of 25-hydroxyvitamin D >30 ng/ml reduces risk for influenza A infection in schoolchildren(Reference Urashima, Segawa and Okazaki12), reduces vascular stiffness in teenagers(Reference Dong, Stallmann-Jorgenson and Pollock6) and reduces risk of cancer in postmenopausal women by 60%(Reference Lappe, Travers-Gustafson and Davies14). The IOM did not suggest that pregnant and lactating women need more than 15 μg vitamin D/d. However in forty mother–infant pairs where 70% of the women were taking on average 15 μg vitamin D/d, it was reported that 76% of the mothers and 81% of the newborns at the time of birth had 25-hydroxyvitamin D level <20 ng/ml(Reference Lee, Smith and Philipp17); a level considered to be vitamin D deficient by the IOM committee. Furthermore it was reported that pre-eclampsia(Reference Bodnar, Catov and Simhan18) and the need for a primary Caesarean section(Reference Merewood, Mehta and Chen19) were associated with vitamin D deficiency.

There is no downside to increasing vitamin D intake. The IOM in its wisdom in 1997 suggested that all children and adults up to the age of 50 years required only 5 μg vitamin D/d. However, thankfully, it has now realized what most experts have been recommending: that this is totally inadequate to satisfy even bone health. It is likely that, as more RCT are reported using higher doses of vitamin D demonstrating non-skeletal beneficial effects, the next meeting will likely increase the recommendation by another threefold. To achieve a blood level of 25-hydroxyvitamin D >30 ng/ml, children aged 1 year and older should ingest 25 μg vitamin D/d and teenagers and all adults require 50 μg vitamin D/d. A study in Finland reported that children who ingested 50 μg vitamin D/d during their first year of life had substantially reduced risk for type 1 diabetes 31 years later. Therefore the tolerable upper limit should be at least 50 μg/d for this age group(Reference Hypponen, Laara and Jarvelin20). Studies in children and teenagers have demonstrated that 50 μg vitamin D/d is safe and effective in treating and preventing vitamin D deficiency, and therefore a tolerable upper limit of 125 μg/d would be reasonable. Teenagers and all adults should be able to tolerate up to 250 μg vitamin D/d and this would be a reasonable tolerable upper limit.

References

1.Committee to Review Dietary Reference Intakes for Calcium and Vitamin D (2010) Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: Institute of Medicine of the National Academies.Google Scholar
2.Wang, TJ, Pencina, MJ, Booth, SL et al. (2008) Vitamin D deficiency and risk of cardiovascular disease. Circulation 117, 503511.CrossRefGoogle ScholarPubMed
3.Dobnig, H, Pilz, S, Scharnagl, H et al. (2008) Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med 168, 13401349.CrossRefGoogle ScholarPubMed
4.Melamed, ML, Michos, ED, Post, W et al. (2008) 25-Hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 168, 16291637.CrossRefGoogle ScholarPubMed
5.Melamed, ML, Muntner, P, Michos, ED et al. (2008) Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease: results from NHANES 2001 to 2004. Arterioscler Thromb Vasc Biol 28, 11791185.CrossRefGoogle ScholarPubMed
6.Dong, Y, Stallmann-Jorgenson, IS, Pollock, NK et al. (2010) A 16-week randomized clinical trial of 2,000 IU daily vitamin D3 supplementation in black youth: 25-hydroxyvitamin D, adiposity, and arterial stiffness. J Clin Endocrinol Metab 95, 45844591.CrossRefGoogle Scholar
7.Reis, JP, von Mühlen, D, Miller, ER 3rd et al. (2009) Vitamin D status and cardiometabolic risk factors in the United States adolescent population. Pediatrics 124, e371e379.CrossRefGoogle ScholarPubMed
8.Kumar, J, Muntner, P, Kaskel, FJ et al. (2009) Prevalence and associations of 25-hydroxyvitamin D deficiency in US children: NHANES 2001–2004. Pediatrics 124, e362e370.Google Scholar
9.Sabetta, JR, DePetrillo, P, Cipriani, RJ et al. (2010) Serum 25-hydroxyvitamin D and the incidence of acute viral respiratory tract infections in healthy adults. PlosOne 5, e11088.CrossRefGoogle ScholarPubMed
10.Moan, J, Porojnicu, AC, Dahlback, A et al. (2008) Addressing the health benefits and risks, involving vitamin D or skin cancer, of increased sun exposure. Proc Natl Acad Sci USA 105, 668673.CrossRefGoogle ScholarPubMed
11.Brehm, JM, Schuemann, B, Fuhlbrigge, AL et al. (2010) Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program study. J Allergy Clin Immunol 126, 5263.CrossRefGoogle ScholarPubMed
12.Urashima, M, Segawa, T, Okazaki, M et al. (2010) Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am J Clin Nutr 91, 12551260.CrossRefGoogle ScholarPubMed
13.Grant, WB (2002) An estimate of premature cancer mortality in the US due to inadequate doses of solar ultraviolet-B radiation. Cancer 70, 28612869.Google Scholar
14.Lappe, JM, Travers-Gustafson, D, Davies, KM et al. (2007) Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 85, 15861591.CrossRefGoogle ScholarPubMed
15.Holick, MF (2007) Vitamin D deficiency. N Engl J Med 357, 266281.CrossRefGoogle ScholarPubMed
16.Adams, JS & Hewison, M (2010) Update in vitamin D. J Clin Endocrinol Metab 95, 471478.CrossRefGoogle ScholarPubMed
17.Lee, JM, Smith, JR, Philipp, BL et al. (2007) Vitamin D deficiency in a healthy group of mothers and newborn infants. Clin Pediatr 46, 4244.CrossRefGoogle Scholar
18.Bodnar, LM, Catov, JM, Simhan, HN et al. (2007) Maternal vitamin D deficiency increases the risk of preeclampsia. J Clin Endocrinol Metab 92, 35173522.CrossRefGoogle ScholarPubMed
19.Merewood, A, Mehta, SD, Chen, TC et al. (2009) Association between vitamin D deficiency and primary cesarean section. J Clin Endocrinol Metab 94, 940945.CrossRefGoogle ScholarPubMed
20.Hypponen, E, Laara, E, Jarvelin, M-R et al. (2001) Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 358, 15001503.CrossRefGoogle ScholarPubMed